232 related articles for article (PubMed ID: 8596127)
1. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.
Read RC; Kuss A; Berrisoul F; Kearsley N; Torres A; Kubin R
Respir Med; 1999 Apr; 93(4):252-61. PubMed ID: 10464889
[TBL] [Abstract][Full Text] [Related]
3. Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis.
Van Royen P; Betz W; Heyrman J; Taziaux P; Van den Haute M; Poelman M
J Int Med Res; 1997; 25(1):33-40. PubMed ID: 9027671
[TBL] [Abstract][Full Text] [Related]
4. Once-a-day therapy for sinusitis: a comparison study of cefixime and amoxicillin.
Edelstein DR; Avner SE; Chow JM; Duerksen RL; Johnson J; Ronis M; Rybak LP; Bierman WC; Matthews BL; Kohlbrenner VM
Laryngoscope; 1993 Jan; 103(1 Pt 1):33-41. PubMed ID: 8421417
[TBL] [Abstract][Full Text] [Related]
5. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
6. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
[TBL] [Abstract][Full Text] [Related]
7. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.
Legnani D; Lombardo VM; Negretto GG; Beghi G; Caratozzolo O
J Hosp Infect; 1992 Nov; 22 Suppl A():69-74. PubMed ID: 1362752
[TBL] [Abstract][Full Text] [Related]
9. Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.
Kafetzis DA
Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):857-65. PubMed ID: 7889960
[TBL] [Abstract][Full Text] [Related]
10. Cefixime versus amoxicillin/clavulanic acid in lower respiratory tract infections.
Beumer HM
Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):30-3. PubMed ID: 2663735
[TBL] [Abstract][Full Text] [Related]
11. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group.
Biebuyck XA
J Int Med Res; 1996; 24(5):407-18. PubMed ID: 8895044
[TBL] [Abstract][Full Text] [Related]
12. Once-a-day cefixime versus co-amoxiclav three times daily in the treatment of lower respiratory infections.
Lieberman D; Schlaeffer F
J Antimicrob Chemother; 1995 Feb; 35(2):354-7. PubMed ID: 7759403
[No Abstract] [Full Text] [Related]
13. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis.
Henry D; Ruoff GE; Rhudy J; Puopolo A; Drehobl M; Schoenberger J; Giguere G; Collins JJ
Clin Ther; 1995; 17(5):861-74. PubMed ID: 8595638
[TBL] [Abstract][Full Text] [Related]
14. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
Gris P
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
[TBL] [Abstract][Full Text] [Related]
15. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
[TBL] [Abstract][Full Text] [Related]
16. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis.
Beghi G; Berni F; Carratù L; Casalini A; Consigli G; D'Antò M; Gioia V; Molino A; Paizis G; Vaghi A
J Chemother; 1995 Apr; 7(2):146-52. PubMed ID: 7666122
[TBL] [Abstract][Full Text] [Related]
18. Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults.
Behler PG; Böge K; Böhning W; Gams W; Gartner-Toth M; Wettengel R
J Chemother; 1995 May; 7 Suppl 1():16-20. PubMed ID: 8618108
[TBL] [Abstract][Full Text] [Related]
19. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.
Zachariah J
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851
[TBL] [Abstract][Full Text] [Related]
20. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
